Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy

Rita Paniccia, Emilia Antonucci, Niccolò Maggini, Eloisa Romano, Anna Maria Gori, Rossella Marcucci, Domenico Prisco, Rosanna Abbate

Research output: Contribution to journalArticle

Abstract

This study sought to compare Multiplate impedance platelet aggregometry (IPA) with light transmission aggregometry (LTA) and the PFA-100 for determining the prevalence of residual platelet reactivity (RPR) by the Multiplate IPA in 297 patients with acute coronary syndrome receiving dual antiplatelet therapy. Aggregations were induced by adenosine-5 diphosphate (ADP), arachidonic acid, and collagen. PFA-100 closure times were measured by collagen and ADP and epinephrine (CEPI) cartridges. Significant correlations were observed between Multiplate IPA and LTA after all stimulations (P <.0001) and between Multiplate IPA (arachidonate and collagen) and PFA-100 CEPI closure time (P <.0001 for both). Cutoff values of Multiplate IPA (for all stimulations) were calculated for the identification of RPR. Between the Multiplate IPA and LTA good agreement was found with all 3 agonists (P <.0001 for all). Multiplate IPA might represent a reliable, handy, rapid tool to monitor antiplatelet therapy in clinical practice and for clinical investigations.

Original languageEnglish
Pages (from-to)834-842
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume131
Issue number6
DOIs
Publication statusPublished - Jun 2009

Keywords

  • Aspirin resistance
  • Clopidogrel resistance
  • Coronary syndrome
  • Light transmission platelet aggregation
  • Multiplate system
  • Point-of-care testing
  • Residual platelet reactivity
  • Whole blood platelet aggregation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy'. Together they form a unique fingerprint.

  • Cite this